LivaNova PLC - Ordinary Shares (LIVN) News
Filter LIVN News Items
LIVN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LIVN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest LIVN News From Around the Web
Below are the latest news stories about LIVANOVA PLC that investors may wish to consider to help them evaluate LIVN as an investment opportunity.
LivaNova Appoints Natalia Kozmina as Chief Human Resources OfficerLONDON, January 06, 2025--LivaNova PLC today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. |
5 Beaten-Down MedTech Stocks Set to Rebound in 2025Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape. |
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant DepressionLONDON, December 18, 2024--LivaNova PLC announced that Brain Stimulation published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. |
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual MeetingLONDON, December 05, 2024--LivaNova PLC today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place Dec. 6-10 in Los Angeles. |
LivaNova PLC's (NASDAQ:LIVN) Stock Has Shown A Decent Performance: Have Financials A Role To Play?LivaNova's (NASDAQ:LIVN) stock up by 4.9% over the past week. We wonder if and what role the company's financials play... |
Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should KnowThe mean of analysts' price targets for LivaNova (LIVN) points to a 37.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary EndpointLIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels. A premarket approval application will be filed soon. |
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare ConferencesLONDON, November 14, 2024--LivaNova PLC announced Vladimir Makatsaria, CEO, will present a general business update during fireside chats at Stifel, Wolfe and Piper in New York. |
Livanova hits sleep apnea trial goals, plans FDA filingLeerink analysts said the results were largely in line with outcomes in a trial of Inspire Medical’s rival device but cautioned that Livanova may have a hard time breaking into the sleep apnea market. |
Goldman Sachs Says Improving Growth Could Propel These 2 Stocks HigherWith the presidential election season behind us, a major source of uncertainty has been lifted, creating an ideal opportunity for investors to reassess their stock portfolios in light of shifting market conditions. In this environment, Goldman Sachs analysts are evaluating individual stocks, pinpointing those best positioned to thrive in a growth-oriented market. We’ve used the TipRanks database to pull up the details on two names that Goldman’s analysts have singled out. Looking at the broader |